4.4 Article

Clinical features and prognostic implications of TCF3-PBX1 and ETV6-RUNX1 in adult acute lymphoblastic leukemia

Journal

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL
Volume 95, Issue 2, Pages 241-246

Publisher

FERRATA STORTI FOUNDATION
DOI: 10.3324/haematol.2009.011346

Keywords

homeobox gene; core binding factor; helix-loop-helix transcription factor; pre-B ALL; common ALL

Categories

Funding

  1. Deutsche Krebshilfe [70-2657-Ho2]
  2. Deutsche Jose Carreras Leukamiestiftung [06122]

Ask authors/readers for more resources

Background The t(9-22) and t(4-11) chromosomal translocations, which generate the BCR-ABL and MLL-AF4 fusion genes, define high-risk subtypes of acute lymphoblastic leukemia in adults. However, the prognostic impact of other rarer fusion genes is less well established in adult acute lymphoblastic leukemia than in the childhood form. Design and Methods In the context of the German Multicenter Therapy Study Group for Adult Acute Lymphoblastic Leukemia (GMALL) we used reverse transcriptase polymerase chain reaction to investigate 441 cases of BCR-ABL- and MLL-AF4-negative B-precursor acute lymphobtastic leukemia for the TCF3-PBX1 (E2A-PBX1) and ETV6-RUAX1 (TEL-AML1) Fusion transcripts generated by the t(1; 19)(q23;p13.3) and t(12;21)(p13;q22) translocations. Both are well-known molecular alterations in pediatric acute lymphoblastic leukemia in which they have favorable prognostic implications. Results We identified 23 adult patients with TCF3-PBX1 and ten with ETV6-RUNX1. In contrast to previous reports we found no significant difference it) overall survival between TCF3-PBX1-positive and -negative patients. At 2 years after diagnosis all the ETV6-RUNX1-positive patients were alive and in continuous complete remission, but their long-term outcome was negatively affected by late relapses. TCF-3-PBX1-positive patients exhibited a characteristic CD34(-)/CD33(-) and mostly cyIg(+) immunophenotype. ETV6-RUNX1 only occurred in patients under 35 years old and was associated with a significantly lower white blood count. Conclusions In contrast to previous suggestions, adult patients with TCF3-PBX1-positive acute lymphoblastic leukemia do not appear to have a worse outcome than their negative counterparts. ETV6-RUANX1-positive patients had a very favorable performance status during the first few years but their long-term survival was negatively affected by late relapses. Both groups of patients are characterized by distinct clinicobiological features which facilitate their diagnostic identification.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Hematology

Acute myeloid leukemia: negative prognostic impact of early blast persistence can be in part overcome by a later remission prior to post-induction therapy

Jana Ihlow, Sophia Gross, Leonie Busack, Anne Floercken, Julia Jesse, Michaela Schwarz, Nina Rosa Neuendorff, Ann-Christin Von Bruenneck, Ioannis Anagnostopoulos, Seval Tuerkmen, Igor Wolfgang Blau, Thomas Burmeister, David Horst, Lars Bullinger, Joerg Westermann

Summary: This retrospective study analyzed the prognostic impact of early bone marrow assessment in 1,008 newly diagnosed acute myeloid leukemia patients. It found that early blast persistence had a negative prognostic impact on overall survival, event-free survival, and relapse-free survival. However, patients who achieved at least partial remission and subsequent blast clearance showed improved outcomes. The study suggests that the time slope of remission can inform post-induction therapy decision-making.

HAEMATOLOGICA (2022)

Letter Oncology

UBTF::ATXN7L3 gene fusion defines novel B cell precursor ALL subtype with CDX2 expression and need for intensified treatment

Lorenz Bastian, Alina M. Hartmann, Thomas Beder, Sonja Haenzelmann, Jan Kaessens, Miriam Bultmann, Marc P. Hoeppner, Soeren Franzenburg, Michael Wittig, Andre Franke, Inga Nagel, Malte Spielmann, Niklas Reimer, Hauke Busch, Stefan Schwartz, Bjoern Steffen, Andreas Viardot, Konstanze Doehner, Mustafa Kondakci, Gerald Wulf, Knut Wendelin, Andrea Renzelmann, Alexander Kiani, Heiko Trautmann, Martin Neumann, Nicola Goekbuget, Monika Brueggemann, Claudia D. Baldus

LEUKEMIA (2022)

Article Oncology

Liquid Biopsy in Colorectal Cancer: Quo Vadis? Implementation of Liquid Biopsies in Routine Clinical Patient Care in Two German Comprehensive Cancer Centers

Laura E. Fischer, Sebastian Stintzing, Volker Heinemann, Ulrich Keilholz, Dietmar Keune, Claudia Vollbrecht, Thomas Burmeister, Andreas Kind, Lena Weiss, David Horst, Thomas Kirchner, Frederick Klauschen, Andreas Jung, Christoph Benedikt Westphalen, Ivan Jelas

Summary: This study retrospectively analyzed the implementation of liquid biopsies (LB) in the clinical management of colorectal cancer (CRC) patients between 2017 and 2021. The results indicate that the potential of LB as a diagnostic tool to drive personalized treatment in CRC patients is not yet fully exploited in everyday clinical practice.

FRONTIERS IN ONCOLOGY (2022)

Article Multidisciplinary Sciences

Clinical relevance of molecular characteristics in Burkitt lymphoma differs according to age

Birgit Burkhardt, Ulf Michgehl, Jonas Rohde, Tabea Erdmann, Philipp Berning, Katrin Reutter, Marius Rohde, Arndt Borkhardt, Thomas Burmeister, Sandeep Dave, Alexandar Tzankov, Martin Dugas, Sarah Sandmann, Falko Fend, Jasmin Finger, Stephanie Mueller, Nicola Goekbuget, Torsten Haferlach, Wolfgang Kern, Wolfgang Hartmann, Wolfram Klapper, Ilske Oschlies, Julia Richter, Udo Kontny, Mathias Lutz, Britta Maecker-Kolhoff, German Ott, Andreas Rosenwald, Reiner Siebert, Arend von Stackelberg, Brigitte Strahm, Wilhelm Woessmann, Martin Zimmermann, Myroslav Zapukhlyak, Michael Grau, Georg Lenz

Summary: This study compares mutational profiles in different age groups of Burkitt lymphoma patients and finds a transition in mutational features between the ages of 25 and 40. There are also differences in the mutation frequencies between pediatric and adult patients. TP53 mutations in pediatric patients are significantly associated with higher relapse incidence.

NATURE COMMUNICATIONS (2022)

Article Immunology

STAT3 gain-of-function is not responsible for low total IgE levels in patients with autoimmune chronic spontaneous urticaria

Merle Sauer, Joerg Scheffel, Stefan Frischbutter, Niklas Mahnke, Marcus Maurer, Thomas Burmeister, Karoline Krause, Martin Metz

Summary: This study aimed to investigate a possible gain-of-function mutation or activating polymorphism in the STAT3 gene responsible for low IgE levels in patients with CSUaiTIIb. However, no differences were found in the prevalence of tested SNPs or mutations in the relevant exons of STAT3, indicating that the low IgE levels in these patients may not be linked to STAT3 mutations or altered activity. Further research is needed to uncover the cause of low IgE levels in CSUaiTIIb patients.

FRONTIERS IN IMMUNOLOGY (2022)

Meeting Abstract Hematology

Therapy-Related AML: Clinical/Biological Features and Long-Term Outcome in a Cohort of 1133 Adult AML Patients

Sophia Gross, Jana Ihlow, Leonie Busack, Kacper Adamiak, Jens F. Schrezenmeier, Julia Jesse, Michaela Schwarz, Anne Floercken, Kathrin Rieger, Jan Kronke, Philipp le Coutre, Vivien Boldt, Ann-Christin Von Bruenneck, David Horst, Thomas Burmeister, Igor Wolfgang Blau, Ulrich Keller, Lars Bullinger, Joerg Westermann

BLOOD (2022)

Article Multidisciplinary Sciences

FAT1 expression in T-cell acute lymphoblastic leukemia (T-ALL) modulates proliferation and WNT signaling

Sven Liebig, Martin Neumann, Patricia Silva, Jutta Ortiz-Tanchez, Veronika Schulze, Konstandina Isaakidis, Cornelia Schlee, Michael P. Schroeder, Thomas Beder, Luc G. T. Morris, Timothy A. Chan, Lorenz Bastian, Thomas Burmeister, Stefan Schwartz, Nicola Goekbuget, Liliana H. Mochmann, Claudia D. Baldus

Summary: FAT atypical cadherin 1 (FAT1), a transmembrane protein, is frequently mutated in various cancer types and has been described as context-dependent tumor suppressor or oncogene. FAT1 expression in T-ALL patients is correlated with promoter methylation status, with a subset of TLX1-driven T-ALL patients showing methylation-independent high FAT1 expression.

SCIENTIFIC REPORTS (2023)

Article Oncology

The KMT2A recombinome of acute leukemias in 2023

C. Meyer, P. Larghero, B. Almeida Lopes, T. Burmeister, D. Groeger, R. Sutton, N. C. Venn, G. Cazzaniga, L. Corral Abascal, G. Tsaur, L. Fechina, M. Emerenciano, M. S. Pombo-de-Oliveira, T. Lund-Aho, T. Lundan, M. Montonen, V. Juvonen, J. Zuna, J. Trka, P. Ballerini, H. Lapillonne, V. H. J. van der Velden, E. Sonneveld, E. Delabesse, R. R. C. de Matos, M. L. M. Silva, S. Bomken, K. Katsibardi, M. Keernik, N. Grardel, J. Mason, R. Price, J. Kim, C. Eckert, L. Lo Nigro, C. Bueno, P. Menendez, U. zur Stadt, P. Gameiro, L. Sedek, T. Szczepanski, A. Bidet, V. Marcu, K. Shichrur, S. Izraeli, H. O. Madsen, B. W. Schaefer, S. Kubetzko, R. Kim, E. Clappier, H. Trautmann, M. Brueggemann, P. Archer, J. Hancock, J. Alten, A. Moericke, M. Stanulla, J. Lentes, A. K. Bergmann, S. Strehl, S. Koehrer, K. Nebral, M. N. Dworzak, O. A. Haas, C. Arfeuille, A. Caye-Eude, H. Cave, R. Marschalek

Summary: This study analyzed the genomic breakpoints in 3401 acute leukemia patients and identified 107 KMT2A gene fusions and other rearrangements. The study also found seven common fusion genes and partial tandem duplications, which are important for understanding the pathogenesis of acute leukemia and monitoring minimal residual disease.

LEUKEMIA (2023)

Article Oncology

Variable outcomes of hepatitis E infections in patients with hemato-oncologic diseases

Viktoria Ingwersen, Joerg Hofmann, Marion Muche, Philipp Le Coutre, Thomas Schneider, Corinna Leng, Thomas Burmeister, Georg Maschmeyer, Ulrich Keller, Stefan Schwartz

Summary: This study retrospectively analyzed 22 immunocompromised patients and found that hepatitis E virus (HEV) could cause chronic infections in these patients. Some patients achieved viral clearance with ribavirin therapy, but others still could not clear the virus and may develop liver failure.

ONCOLOGY RESEARCH AND TREATMENT (2023)

Article Oncology

A pooled subgroup analysis of glucarpidase treatment in 86 pediatric, adolescent, and young adult patients receiving high-dose methotrexate therapy in open-label trials

Katherine A. Janeway, Luis Gros, Stefan Schwartz, Claire Daugherty, Eva Gallardo, Christon Hill, Emma Thomas, Suzanne Ward, Carmelo Rizzari

Summary: Delayed elimination of methotrexate can occur in cancer treatment. Compassionate-use trials showed the effectiveness of glucarpidase in rapidly reducing methotrexate concentrations. This study analyzed pediatric and young adult patients and confirmed the efficacy and safety of glucarpidase in this population.

PEDIATRIC BLOOD & CANCER (2023)

Article Multidisciplinary Sciences

Molecular characterization of TCF3::PBX1 chromosomal breakpoints in acute lymphoblastic leukemia and their use for measurable residual disease assessment

Thomas Burmeister, Daniela Groeger, Nicola Goekbuget, Bernd Spriewald, Michael Starck, Ahmet Elmaagacli, Dieter Hoelzer, Ulrich Keller, Stefan Schwartz

Summary: The translocation t(1;19)(q23;p13) with the resulting chimeric TCF3::PBX1 gene is the third most prevalent recurrent chromosomal translocation in acute lymphoblastic leukemia. This study provides extensive molecular data on the chromosomal breakpoints of this translocation in adult patients and explores the feasibility of using patient-specific chromosomal break sites as molecular markers for detecting measurable residual disease (MRD). A highly sensitive generic real-time PCR for MRD assessment using these breakpoint sequences was established, offering a potential alternative to the classical method utilizing rearranged immune gene loci.

SCIENTIFIC REPORTS (2023)

Article Hematology

The Recurrent Atypical e8a2 BCR::ABL1 Transcript with Insertion of an Inverted 55 Base Pair ABL1 Intron 1b Sequence: A Detailed Molecular Analysis

Thomas Burmeister, Lars Bullinger, Philipp le Coutre

Summary: Atypical BCR-ABL1 transcripts, present in approximately 2% of chronic myeloid leukemia cases, should be detected as patients with these transcripts can benefit from tyrosine kinase inhibitor therapy. In the e8a2 atypical BCR-ABL1 transcript, two out-of-frame exons are fused, typically with interposed nucleotides to restore the reading frame. This study analyzes a specific e8a2 BCR-ABL1 translocation, identifies the genomic chromosomal breakpoint, explains the formation of this transcript, and provides recommendations for molecular analysis of future e8a2 BCR-ABL1 cases.

ACTA HAEMATOLOGICA (2023)

Meeting Abstract Oncology

Therapy-associated AML: clinical/biological characteristics and long-term prognosis in a large cohort of AML patients

S. Gross, J. Ihlow, L. Busack, K. Adamiak, J. Jesse, M. Schwarz, K. Rieger, J. Kroenke, P. le Coutre, A. C. von Bruenneck, D. Horst, T. Burmeister, I. W. Blau, U. Keller, L. Bullinger, J. Westermann

ONCOLOGY RESEARCH AND TREATMENT (2022)

No Data Available